|
|
Strategic Analysis of U.S. Genomics MarketsPublished by: Frost & Sullivan Published: Dec. 20, 2006 Table of Contents 1. Introduction AbstractResearch OverviewThe Frost & Sullivan research service entitled Strategic Analysis of U.S. Genomics Markets provides revenue forecasts for the overall market, the U.S. nucleic acid isolation markets, the U.S. PCR markets, the U.S. qRT-PCR markets, the U.S. DNA microarray markets, and the U.S. DNA sequencing technology markets with detailed market trends for specific applications, end users, and technologies. Moreover, the research service provides an in-depth analysis of market-wide and segment-specific drivers, restraints, and challenges with the corresponding strategic recommendations. In this research service, Frost & Sullivan's expert analysts thoroughly examine the total U.S. genomics markets, the markets for U.S. nucleic acid isolation markets, U.S. PCR markets, U.S. qRT-PCR markets, U.S. DNA microarray markets, and U.S. DNA sequencing technology markets. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research: By Application:
Next Generation Genomics Technologies Providing Fresh Impetus While the days of high market growth, driven by the human genome project, are behind us, the era of personal genomics is yet to come. However, the realization of personal genomics is being hindered by genomics platforms that are too inefficient and expensive for ultra-high throughput comprehensive genome-wide analyses. Consequently, markets for last-generation genomics technologies, such as general polymerase chain reaction (PCR) and conventional deoxyribonucleic acid (DNA) sequencing, are beginning to stabilize. Concurrently, next generation genomics technologies are breathing new life into the market, and are expected to contribute a compound annual growth rate (CAGR) of 10.4 percent between 2005 and 2012. However, high instrument costs continue to be a major barrier for market growth. High instrument costs often result in a centralized installed base, which challenges market participants that hope to grow instrument-driven revenue generation. Moreover, receiving Federal Drug Administration (FDA) approval is another challenge for market participants that want to enter the clinical diagnostics market. "The uncertain path to personalized genomics often complicates competitive strategies," notes the analyst of this research service. "Vendors will have to formulate strategies with an appreciation for the evolving aims of genomics research and also maintain a broad value proposition with relation to discovery, validation, and commercialization." qRT-PCR Technologies Emerge as the Fastest Growing Segment Among the market segments, quantitative reverse transcriptase (qRT)-PCR technology, including instrumentation and reagents, is developing as the fastest growing segment of the total U.S. genomics market. As researchers attempt to validate discoveries made on the foundation of The Human Genome Project, they find technologies such as qRT-PCR ideal for their targeted studies. Following the qRT-PCR segment, DNA microarray technology is developing as the second-fastest growing segment of the total U.S. genomics market. While genome-wide expression analyses are forecasted to drive the majority of DNA microarray segment growth, markets related to novel genomics analyses, such as comparative genomic hybridization (CGH), genome-wide methylation studies, and chromatin immunoprecipitation (ChIP)-chip, are likely to see the highest growth. Finally, the majority of the DNA sequencing technology segment growth is anticipated to result from the introduction and extensive placement of next generation DNA sequencing technologies. With respect to the market structure, there are approximately 150 companies that participate in the total U.S. genomics market. Market participants include well-established life science supply companies, medium-sized companies that focus exclusively on market segments, and small, niche companies. "Top industry participants are successfully developing specific applications for each evolutionary stage of the genomics market," says the analyst. "Leading companies are likely to maintain revenue streams, while strategically positioning themselves for the significant penetration of future markets for clinical applications of genomic technologies." Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||